AMP German Cannabis Group has announced that The Office of Medical Cannabis (“OMC”), the government organization of the Netherlands for distribution of medical cannabis products, notified AMP that it has postponed selling EU-GMP medical cannabis to additional importers, including AMP, until further notice.
AMP has received all the required licenses to import irradiated cannabis flowers from the Dutch and German government authorities. During May, AMP placed its first order to import two Bedrocan International branded products from OMC, which subsequently confirmed receipt of AMP’s order.
In addition, the Company completed the audit of its supply chain to ensure the quality and integrity of the pharmaceutical goods is maintained during transportation, warehousing, handling, testing and distribution from foreign medical cannabis suppliers to distributors in Germany.
Dr. Stefan Feuerstein, Director and President of AMP, commented: “It is our understanding that German and Dutch government authorities are currently negotiating new export quotas for medical cannabis. AMP will be able to procure supply from the Netherlands once the OMC increases its production supply for export and supply restrictions are lifted. Independent from that, we are in very advanced negotiations with several foreign cannabis producers who already have an EU-GMP certification and are expecting to sign at least one definitive supply agreement within the next month. Our potential suppliers generally operate cultivation facilities with an annual production capacity between 5,000 and 10,000 kg.”
For more information:
AMP German Cannabis Group
Charlottenstraße 59
10117 Berlin, Germany
investor@amp-eu.de
investor@amp-eu.com
amp-eu.com